Works matching AU Rau, Kun-Ming

Results: 48
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Anti-tumor efficacy of a bevacizumab preconditioning followed by etoposide and cisplatin regimen in human epidermal growth factor receptor-2-positive breast cancer brain metastasis refractory to whole brain radiotherapy.

    Published in:
    Journal of Cancer Research & Practice, 2023, v. 10, n. 1, p. 11, doi. 10.4103/ejcrp.eJCRP-D-23-00001
    By:
    • Chen, Tom;
    • Lin, Ching-Hung;
    • Yeh, Dah-Cherng;
    • Tseng, Ling-Ming;
    • Rau, Kun-Ming;
    • Chen, Bang-Bin;
    • Chao, Ta-Chung;
    • Huang, Shu-Min;
    • Chang, Dwan-Ying;
    • Chen, I-Chun;
    • Cheng, Ann-Lii;
    • Lu, Yen-Shen
    Publication type:
    Article
    12
    13
    14
    15
    16
    17

    A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases.

    Published in:
    PLoS ONE, 2016, v. 11, n. 12, p. 1, doi. 10.1371/journal.pone.0167923
    By:
    • Chen, Yu-Mu;
    • Fang, Ying-Tang;
    • Lai, Chien-Hao;
    • Rau, Kun-Ming;
    • Huang, Cheng-Hua;
    • Chang, Huang-Chih;
    • Chao, Tung-Ying;
    • Tseng, Chia-Cheng;
    • Fang, Wen-Feng;
    • Wang, Chin-Chou;
    • Chen, Yung-Che;
    • Chung, Yu-Hsiu;
    • Wang, Yi-Hsi;
    • Su, Mao-Chang;
    • Liu, Shih-Feng;
    • Huang, Kuo-Tung;
    • Chen, Hung-Chen;
    • Chang, Ya-Chun;
    • Chang, Yu-Ping;
    • Lin, Meng-Chih
    Publication type:
    Article
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29

    Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.

    Published in:
    Breast Cancer Research & Treatment, 2018, v. 170, n. 3, p. 583, doi. 10.1007/s10549-018-4778-y
    By:
    • Rau, Kun-Ming;
    • Ou-Yang, Fu;
    • Chao, Ta-Chung;
    • Kuo, Yao-Lung;
    • Cheng, Tsui-Fen;
    • Chao, Tsu-Yi;
    • Chen, Dar-Ren;
    • Tzeng, Yen-Dun;
    • Wang, Being-Whey;
    • Liu, Chun-Yu;
    • Hu, Ming-Hung;
    • Lu, Yin-Che;
    • Ou, Wei-Jen;
    • Kuo, Chin-Ho;
    • Chuang, Chieh-Han;
    • Kan, Jung-Yu;
    • Chen, Fang-Ming;
    • Hou, Ming-Feng
    Publication type:
    Article
    30
    31
    32
    33
    34

    Satisfaction with pain management and impact of pain on quality of life in cancer patients.

    Published in:
    Asia Pacific Journal of Clinical Oncology, 2020, v. 16, n. 2, p. e91, doi. 10.1111/ajco.13095
    By:
    • Lin, Johnson;
    • Hsieh, Ruey‐Kuen;
    • Chen, Jen‐Shi;
    • Lee, Kuan‐Der;
    • Rau, Kun‐Ming;
    • Shao, Yu‐Yun;
    • Sung, Yung‐Chuan;
    • Yeh, Su‐Peng;
    • Chang, Cheng‐Shyong;
    • Liu, Ta‐Chih;
    • Wu, Ming‐Fang;
    • Lee, Ming‐Yang;
    • Yu, Ming‐Sun;
    • Yen, Chia‐Jui;
    • Lai, Pang‐Yu;
    • Hwang, Wen‐Li;
    • Chiou, Tzeon‐Jye
    Publication type:
    Article
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44

    Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens

    Published in:
    Breast Cancer Research & Treatment, 2021, v. 189, n. 3, p. 665, doi. 10.1007/s10549-021-06313-5
    By:
    • Dai, Ming Shen;
    • Feng, Yin Hsun;
    • Chen, Shang Wen;
    • Masuda, Norikazu;
    • Yau, Thomas;
    • Chen, Shou Tung;
    • Lu, Yen Shen;
    • Yap, Yoon Sim;
    • Ang, Peter C. S.;
    • Chu, Sung Chao;
    • Kwong, Ava;
    • Lee, Keun Seok;
    • Ow, Samuel;
    • Kim, Sung Bae;
    • Lin, Johnson;
    • Chung, Hyun Cheol;
    • Ngan, Roger;
    • Kok, Victor C.;
    • Rau, Kun Ming;
    • Sangai, Takafumi
    Publication type:
    Article
    45

    Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression.

    Published in:
    Liver Cancer (2235-1795), 2024, v. 13, n. 5, p. 509, doi. 10.1159/000536549
    By:
    • Liu, Tsung-Hao;
    • Chen, San-Chi;
    • Rau, Kun-Ming;
    • Lu, Li-Chun;
    • Lin, Po-Ting;
    • Su, Yung-Yeh;
    • Teng, Wei;
    • Lai, Shiue-Wei;
    • Yeh, Ren-Hua;
    • Kao, Tsui-Mai;
    • Lee, Pei-Chang;
    • Wu, Chi-Jung;
    • Chen, Chien-Hung;
    • Hsu, Chih-Hung;
    • Lin, Shi-Ming;
    • Huang, Yi-Hsiang;
    • Chen, Li-Tzong;
    • Cheng, Ann-Lii;
    • Shen, Ying-Chun
    Publication type:
    Article
    46

    Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).

    Published in:
    Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 451, doi. 10.1159/000516605
    By:
    • Kudo, Masatoshi;
    • Finn, Richard S.;
    • Morimoto, Manabu;
    • Rau, Kun-Ming;
    • Ikeda, Masafumi;
    • Yen, Chia-Jui;
    • Galle, Peter R.;
    • Llovet, Josep M.;
    • Daniele, Bruno;
    • Lim, Ho Yeong;
    • McIlwain, David W.;
    • Yoshikawa, Reigetsu;
    • Nakamura, Kenichi;
    • Liang, Kun;
    • Wang, Chunxiao;
    • Abada, Paolo;
    • Widau, Ryan C.;
    • Zhu, Andrew X.
    Publication type:
    Article
    47

    Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).

    Published in:
    Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 451, doi. 10.1159/000516605
    By:
    • Kudo, Masatoshi;
    • Finn, Richard S.;
    • Morimoto, Manabu;
    • Rau, Kun-Ming;
    • Ikeda, Masafumi;
    • Yen, Chia-Jui;
    • Galle, Peter R.;
    • Llovet, Josep M.;
    • Daniele, Bruno;
    • Lim, Ho Yeong;
    • McIlwain, David W.;
    • Yoshikawa, Reigetsu;
    • Nakamura, Kenichi;
    • Liang, Kun;
    • Wang, Chunxiao;
    • Abada, Paolo;
    • Widau, Ryan C.;
    • Zhu, Andrew X.
    Publication type:
    Article
    48